Research programme: anabolic peptides - OsteopharmAlternative Names: Anabolic peptides research programme - Osteopharm
Latest Information Update: 18 Jul 2006
At a glance
- Originator Osteopharm
- Mechanism of Action Osteogenesis stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Postmenopausal osteoporosis
Most Recent Events
- 18 Jul 2006 No development reported - Preclinical for Postmenopausal osteoporosis in Canada (unspecified route)
- 22 Mar 2002 Osteopharm has been sold by GenSci Regeneration Sciences
- 02 Mar 1999 New profile